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Abstract By taking advantage of some recently synthesized
compounds that are able to block ecto-ATPase activity, we
demonstrated that adenosine triphosphate (ATP) in the hippo-
campus exerts an inhibitory action independent of its degrada-
tion to adenosine. In addition, tonic activation of P2 receptors
contributes to the normally recorded excitatory neurotransmis-
sion. The role of P2 receptors becomes critical during ischemia
when extracellular ATP concentrations increase. Under such
conditions, P2 antagonism is protective. Although ATP exerts a
detrimental role under ischemia, it also exerts a trophic role in
terms of cell division and differentiation. We recently reported
that ATP is spontaneously released from human mesenchymal
stem cells (hMSCs) in culture. Moreover, it decreases hMSC
proliferation rate at early stages of culture. Increased hMSC
differentiation could account for an ATP-induced decrease in
cell proliferation. ATP as a homeostatic regulator might exert a
different effect on cell trophism according to the rate of its
efflux and receptor expression during the cell life cycle. During
ischemia, adenosine formed by intracellular ATP escapes from
cells through the equilibrative transporter. The protective role of
adenosine A1 receptors during ischemia is well accepted.
However, the use of selective A1 agonists is hampered by
unwanted peripheral effects, thus attention has been focused on
A2A and A3 receptors. The protective effects of A2A antagonists
in brain ischemia may be largely due to reduced glutamate
outflow from neurones and glial cells. Reduced activation of
p38 mitogen-activated protein kinases that are involved in
neuronal death through transcriptional mechanisms may also
contribute to protection by A2A antagonism. Evidence that A3
receptor antagonism may be protective after ischemia is also
reported.
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Historical overview
The physiological roles of adenosine triphosphate (ATP) and
its metabolite adenosine have been historically linked to cell
metabolism since ATP is an ubiquitous intracellular energy
sourceinanumberofenzymaticprocesses.However,overthe
years both metabolites have emerged as very versatile
molecules of biological systems, being implicated in a variety
of cell processes, from platelet aggregation to neurotransmis-
sion. The term ‘purinergic signalling’ was first introduced in
the scientific literature by Burnstock [1]. An implicit concept
for sustaining the hypothesis of purinergic neurotransmission
proposed in the 1970s was the existence of purinergic recep-
tors. The first evidence in this direction suggested the exist-
ence of two different subfamilies of such ‘purinoceptors’,
identified as P1 and P2 receptors, selective for adenosine and
ATP respectively [2]. Four different subtypes of P1-G-protein-
coupled receptors: A1,A 2A,A 2B and A3 are known at present
[3], whereas P2 purinoceptors belong to two major families:
P2X ligand-gated ion channel receptors and P2Y G-protein-
coupled receptors [4]. Cloning experiments supported this
classification and helped to subdivide P2 receptors into seven
P2X and eight P2Y subtypes [5] (plus the recently deorphan-
ized GPR17 receptor [6]).
Roles of ATP in neurotransmission under normoxic
conditions
The first studies on the role of extracellular ATP in hippo-
campal neurotransmission indicated prominent inhibitory
action of this purinergic nucleotide on synaptic activity [7,
8]. However, several lines of evidence led to the hypothesis
that ATP-mediated inhibition of hippocampal neurotransmis-
sion was probably mediated by adenosine acting on A1
receptors. In fact, this response was theophylline-sensitive
[7–9] and absent in A1 knockout mice [10]. This assumption
was supported by the fact that, in the hippocampus,
extracellular ATP is rapidly converted into adenosine by
ecto-ATPases and ecto-nucleotidases [11] and that adenosine
acting on A1 receptors exerts a well-described inhibitory role
on CA1 excitatory neurotransmission [3]. In recent years, a
more detailed observation of ATP-evoked effects, supported
by the synthesis of new pharmacological tools, has helped to
clarify the effective role of purinergic nucleotides in the
hippocampus. In particular, it emerged that ATP mediates
inhibitory effects by P2 receptor activation [12–14].
In a recent paper, we contributed to elucidating the role
of ATP on CA1 hippocampal neurotransmission, and we
reinforced the concept that ATP-mediated effects are not
necessarily linked to adenosine formation in this brain
region [15]. ATP is hydrolysed by ecto-NTPDase, enzymes
located on the cell surface in the CNS that limit ATP, ADP
and AMP spatio-temporal activity [11, 16]. There are three
different known NTPDases: NTPDase1 hydrolyzes ATP
and ADP equally well, NTPDase2 has a high preference for
ATP, NTPDase3 is a functional intermediate, preferably
hydrolyzing ATP [17]. In our study, we took advantage of
some recently synthesized compounds: ARL 67156, which,
at micromolar concentrations, inhibits rat NTPDase1 and 3
transiently transfected in Chinese hamster ovary cells,
showing negligible activity on NTPDase2 [18]; BGO 136,
a new inhibitor described as a selective NTPDase1 and 2
blocker with Ki values in the high micromolar range [19];
and the recently synthesized PV4, which strongly inhibits
rat NTPDase1, 2 and 3 with Ki values in the nanomolar
range [20]. By using these inhibitors that are able to block
NTPDase activity without interfering with P2 receptor
activation, we demonstrated that ATP exerts an inhibitory
action,independent ofits degradation toadenosine. As shown
in Fig. 1, the application of ATP during a NTPDase activity
blockade still elicits a decrease in evoked synaptic responses
w h i c hi se v e nm o r ep r o n o u n c e dt h a nt h a te v o k e db yA T P
alone.
An excitatory effect of exogenous ATP on hippocampal
neurotransmission has alsobeen reported bydifferentauthors.
This effect, which was observed after drug removal, was
described to persist in in vitro preparations for a relatively
prolonged period, up to 1 h [21–25]. This ‘long-lasting’
potentiation of synaptic responses was compared to electri-
cally evoked LTP, firstly described in the hippocampus by
Abrams and Kandel [26] and called ‘ATP-induced LTP’.I n
agreement, we observed a potentiation of the synaptic re-
sponses after drug removal when slices were superfused in
the presence of the metabolically stable ATP-analogue ATPγS
(Fig. 2)[ 15]. In addition to this ‘long-lasting’ excitatory effect
evoked by the exogenous application of P2 agonists, we also
demonstrated an excitatory tone exerted by endogenous ATP.
300 Purinergic Signalling (2007) 3:299–310Slices superfused with P2 antagonists show a small but
significant reduction in synaptic transmission (Fig. 3). These
data demonstrate that tonic activation of P2 receptors
contributes to glutamatergic excitatory neurotransmission in
the hippocampus, an observation that is in line with previous
work [27].
Roles of ATP in ischemic conditions
The role of ATP may become critical during pathological
conditions such as ischemia, when extracellular ATP concen-
trations increase. An enhanced outflow of radioactive ATP
from hippocampal slices during in vitro ischemic-like insults
was first reported by Juranyi and co-workers [28], and the
first demonstration that ATP outflow increases in vivo during
the induction of focal ischemia in the rat was reported by
Melani and colleagues [29]. Thus, at the ischemic site, levels
of extracellular nucleotides may remain elevated for long
periods of time after injury. Evidence supports the idea that,
under such pathological conditions, released ATP may exert
an excitotoxic role by acting on its receptors, thus enhancing
Ca
2+ inward currents and altering synaptic activity and
cellular plasticity. Non-selective antagonists of P2 receptors,
suramin and PPADS, and the selective antagonists, BBG and
MRS 2179 of P2X7 and P2Y1 receptors respectively, prevent
the irreversible failure of neurotransmission induced by a
prolonged period of OGD in hippocampal slices [15].
Moreover, they protect from development of anoxic depo-
larization (AD), which is a rapid and regenerative wave of
depolarization that propagates in tissue and represents an
unequivocal sign of sufferance [15]. Antagonists of P2
receptors have been proved protective against cell death
induced by either ATP itself, hypoglycemia or glutamate
exposure in primary cultures of brain-derived neurones [30–
33]. Intrastriatal ATP injection in rats induced, 24 h later, a
clearly lesioned area [34]. The ATP-induced damage was
concentration-dependent, mimicked by ATPγS and α,β
meATP (but not by ADP or adenosine) and blocked by
RB2, a non-specific P2 antagonist [34]. Suramin, another
non-specific P2 receptor antagonist, administered 30 min
before occlusion of the middle cerebral artery, resulted in a
significant decrease in infarct and oedema volume 6 h after
brain injury [35]. In agreement, it was demonstrated that
RB2 [36]a n dP P A D S[ 37] improve neurological deficit and
Fig. 1a, b The inhibitory effect induced by ATP on fEPSP amplitude
is potentiated in the presence of different NTPDase inhibitors. a Time-
course of fEPSP amplitude before, during and after the application of
ATP in the absence or in the presence of the NTPDase1,2,3 inhibitor
PV4. Each point in the graph represents the mean ± SE of fEPSP
value measured as percent of baseline, pre-drug level. b Columns in
the graph summarize the average amplitude (mean ± SE) of evoked
fEPSP recorded from CA1 hippocampal region in control conditions,
5 min after superfusion of ATP alone and 5 min after ATP superfusion
in the presence of different ecto-ATPases inhibitors. Note that the
inhibitory effect of ATP on fEPSP amplitude is potentiated by BGO
136, PV4 and ARL 67156. *P<0.05 one-way ANOVA, Newman-Keuls
multiple comparison post-hoc test versus pre-drug value. §P<0.05, one-
way ANOVA, Newman-Keuls multiple comparison post-hoc test versus
10 μM ATP treated slices. (Modified from [15])
Fig. 2 Inhibitory and excitatory effects of the stable ATP analogue
ATPγS. Averaged time-course (n=4) of PS amplitude before, during
and after the application of different concentrations of ATPγS. PS
amplitude (mean ± SE) is measured as percent of baseline level.
Upper panels represent single traces recorded in a typical experiment
before, during and after ATPγS application at different concentrations
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ischemia in vivo. Moreover, RB2 induces the expression of
P2X7 receptors on reactive microglia in the remote ipsi and
contralateral cingulate and medial frontal cortex and stria-
tum. Although a pro-apoptotic role has been attributed to the
P2X7 receptor, results suggest that microglial cells express-
ing the P2X7 receptor can be implicated in tissue damage as
well as in the defence and repairing processes in the remote
ipsi and contralateral undamaged areas [36].
In considering the effect of ATP during ischemia, it must be
taken into account that ATP itself is involved in control of
cerebrovascular regulation [38] and that the metabolite of ATP,
ADP, that interacts with P2Y1/P2Y12 receptors, is a potent
platelet aggregator. However, clinical studies that checked the
antiplatelet therapy of the selective P2Y12 receptor antagonist
clopidogrel reported a response variability [39, 40].
Although evidence suggests that ATP exerts a detrimental
role under ischemia, there are reports that it may exert a
trophic roleinterms ofcelldivisionanddifferentiationinboth
differentiated and undifferentiated cells [41–43], including
adult neural stem cells [44]. Interesting data correlate these
trophic effects with the occurrence of spontaneous Ca
2+
waves that propagate among adjacent cells in a self-renewing
manner. Kawano et al. [45] reported that ATP-induced
initiation and propagation of intracellular Ca
2+ waves in
human mesenchymal stem cells (hMSCs) promote activation
of transcription factors (e.g. NFAT) that are involved in cell
differentiation. In the same study, they demonstrated that
ATP-induced Ca
2+ waves disappear in the fully differentiated
adipogenic phenotype. We recently reported that ATP is
spontaneously released from hMSCs during the early stages
of culture (P0-P5). Moreover, we reported that ATP de-
creases proliferation rate (Fig. 4) and modulates specific
ionic current hMSCs [46]. A high extracellular ATP concen-
tration at earlier cell culture passages suggests an important
role of ATP in regulating cell differentiation. Increased
hMSC differentiation may account for an ATP-induced
decrease in cell proliferation.
Therefore, it can be envisaged that ATP, as an autocrine/
paracrine homeostatic regulator, exerts different effects on
Fig. 3 Excitatory effects of
endogenous ATP. Bars in the
graphs represent the average of
fEPSP amplitude in the presence
of P2 antagonists: PPADS
(30 μM) and MRS 2179
(10 μM). *P<0.05, paired
Student’s t-test. (Modified
from [15])
Fig. 4a, b Human mesenchymal stem cells in culture spontaneously
release ATP that modulates cell proliferation. a Extracellular concen-
trations of ATP were measured in the medium containing hMSCs and in
control medium not containing cells. Data are expressed as mean ± SE,
n=11, unpaired Student’s t-test: *P<0.0001 vs medium alone. b Effect
on hMSC proliferation after daily application of ATP (10 μM) and P2
antagonists, PPADS (30 μM) and MRS 2179 (10 μM). Data are
expressed as percentage of proliferation. Proliferation of untreated cells
was assumed as 100%. The cell number was determined after 5 days of
culture by a culture counter. Each column bar represents the mean ± SE
of n=4 for each experimental condition. Paired Student’s t-test: *P<
0.05 vs respective control; one-way ANOVA, Newman-Keuls post-test:
§P<0.05 vs 10 μM ATP-treated cells. (Modified from [46])
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distinct cell populations involved, differential expression
and recruitment of P2 receptors and of more or less sus-
tained stimulation of the same receptor. Balancing these
effects may be relevant in the post-ischemic brain, when a
neuroregenerative process could promote tissue repair [47].
On this basis, determination of ATP extracellular concen-
trations at various times after ischemia induction may help
to identify which types of receptors may be stimulated
under ischemia and explain the role of detrimental versus
trophic ATP during ischemia. ATP present in the extracellular
space is rapidly metabolised by membrane-bound NTPDase.
Extracellular ATP concentrations, evaluated in the brain to
date, have been underestimated, since it has not been possible
to selectively inhibit ecto-NTPDase. In fact, the selective
inhibitor ARL 67156, tentatively used thus far to inhibit ecto-
NTPDase, interferes with the ATP assay method [29].
Role of adenosine in cerebral transmission under
normoxic conditions
Adenosine exerts an important tonic modulation of synaptic
transmission in the brain. This tonic inhibition of synaptic
transmission is evoked by stimulation of A1 receptors, as
demonstrated in several brain regions, such as the hippo-
campus, striatum and olfactory cortex [48, 49]. The
inhibitory effect of adenosine A1 receptor stimulation has a
pre- and postsynaptic component. Activation of the presyn-
aptic A1 receptors reduces Ca
2+ influx through the preferen-
tial inhibition of N-type and, probably, Q-type channels [50,
51]. Inhibition of presynaptic calcium currents decreases
transmitter release [52], and adenosine, by stimulation of A1
receptors, has been found to inhibit the release of virtually all
classical neurotransmitters: glutamate, acetylcholine, dopa-
mine, noradrenaline and serotonin (see in [53]). In particular,
powerful suppression of glutamate release from presynaptic
terminals has been described in the hippocampus [54, 55],
where adenosine A1 receptor activation reduces the number
of quanta released (but not the size of individual quanta nor
postsynaptic glutamate receptor sensitivity) in the Schaffer
collateral-commissural pathway [56]. The postsynaptic effect
of A1 receptors consists of direct hyperpolarisation of
neurones via activation of GIRK channels (Kir 3.2 and 3.4
channels: potassium inward rectifiers) [57, 58]. Endogenous
adenosine exerts tonic inhibition of excitatory neurotrans-
mission. The selective A1 antagonist, DPCPX, causes a 15%
increase in synaptic potential amplitude in in vitro brain
slices [59]. This is an expected result in a brain region where
the adenosine concentration at a receptor level was calculated
around 200 nM [59, 60]a n dA 1 receptors, whose affinity for
adenosine is in the low nanomolar range, are highly ex-
pressed. These data are confirmed by the fact that, in slices
taken from homozygous A1 receptor knockout mice, no
evidence was found for an endogenous inhibitory action by
adenosine in the Schaffer collateral pathway in the CA1
region of the hippocampus or at the mossy fibre synapses in
the CA3 region [61].
Opposite effects from A1-mediated synaptic inhibition are
elicited by A2A receptor activation, which has been shown to
mediate excitatory actions in synaptic function [62–64]. In
the hippocampus in vitro, A2A receptor stimulation results in
aC a
2+-dependent release of acetylcholine [65, 66]. Further-
more, the application of CGS 21680, a selective A2A receptor
agonist, decreases the ability of A1 receptor agonists to inhibit
excitatory neurotransmission [9, 67]. This effect suggests
that A2A receptor stimulation increases synaptic transmission
through A1 receptor desensitisation [68, 69]. However, there
is also evidence that A2A receptors increase excitatory amino
acid release. In fact, the selective stimulation of adenosine
A2A receptors augments the amount of glutamate released in
the hippocampus and striatum of young rats [70–72].
In spite of the excitatory role in neurotransmission
brought about by A2A receptors, the net effect of adenosine
is an inhibitory tonus on neurotransmission, in accordance
with observations suggesting that activation of A2A receptors
requires protracted stimulation to induce evident effects on
synaptic transmission [59]. It is worth noticing that the role
of A2A receptors in the striatum is recently gaining interest in
light of their heterodimerisation with D2 dopamine receptors.
The association between A2A and D2 receptors results in an
antagonistic interaction that provides a rationale for evaluat-
ing A2A-selective antagonists in Parkinson’sd i s e a s e ,s u p -
ported by epidemiological evidence indicating an inverse
relationship between caffeine consumption and the risk of
developing this pathology [73, 74]. It was suggested that
A2A antagonists not only provide symptomatic relief but also
decelerate dopaminergic neurone degeneration in patients.
Discrepancies about the role of adenosine A3 receptors in
the brain are present in the literature. Activation of this
receptor subtype has been associated with both excitatory
and inhibitory effects, even in the same brain region. An
excitatory role of A3 receptors has been supported by
evidence indicating that, in the rat hippocampus, their activ-
ation attenuates LTD and allows induction of LTP elicited by
a subliminal weak-burst protocol [75]. In addition, in the
same brain area, A3 receptor activation through a selective
adenosine A3 agonist has been shown to antagonize the
adenosine A1 receptor-mediated inhibition of excitatory
neurotransmission [8]. Moreover, A3 receptor stimulation
always attenuates the inhibition of hippocampal slice neuro-
transmission, in a PKC-dependent manner, caused by pre-
synaptic metabotropic glutamate receptors [76]. Whole-cell
patch clamp recordings in CA3 hippocampal pyramidal
neurones demonstrate that A3 receptor activation results in a
significant potentiation of high threshold hippocampal Ca
2+
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facilitation of the onset of epileptiform discharge has been
observed in the presence of the selective A3 receptor agonist
Cl-IB-MECA [78], and a reduction in such epileptic activity
w a so b s e r v e dw h e nA 3 receptors, activated by endogenously
released adenosine during seizures, were blocked by the
selective antagonist MRS 1191 [79].
Contrary to previous results, an inhibitory action has been
attributed to A3 receptors by Brand and colleagues [80], who
demonstrated that, in rat cortical neurones, the selective
activation of this adenosine receptor subtype is involved
in inhibition of excitatory neurotransmission, suggesting a
synergistic action with the inhibitory effect of adenosine
brought about by A1 receptor activation. Despite results
obtained by A3 receptor stimulation, evidence that a selective
block of A3 receptors does not affect neurotransmission in
the CA1 region of the hippocampus under normoxic con-
ditions indicates that endogenous adenosine at physiological
concentrations does not exert tonic activation of A3 receptors
[8, 81]. This is in line with evidence that A3 receptor activ-
ation requires micromolar levels of extracellular adenosine,
which can be reached only during pathological conditions of
impairment in energy supply (for example during hypoxia or
ischemia [82–85]).
Role of adenosine in ischemic conditions
Extracellular adenosine concentrations increase dramatical-
ly during ischemia [82, 86, 87]. During ischemia, following
the imbalance between ATP degradation and resynthesis,
the intracellular concentration of adenosine increases.
Therefore, increased adenosine concentrations in the extra-
cellular space during ischemia are likely due to the equil-
ibrative transporter that carries adenosine out of cells.
Adenosine formation can also take place at the extracellular
level, through the hydrolysis of extracellular ATP operated by
NTPDases and ecto-5′-nucleotidase (e5′-NTs) (see Fig. 5).
Hence, these enzymes have a dual function in modulating
purinergic neurotransmission: (1) they rapidly interrupt ATP-
mediated signalling by degrading extracellular nucleotides
and (2) they give rise to extracellular adenosine, which
activates P1 receptors. However, recent evidence in vitro
suggests that released ATP does not substantially contribute
to the adenosine concentration in the extracellular milieu
during ischemia [88].
Adenosine-potentiating agents, which elevate endogenous
adenosine levels by either inhibiting its metabolism by
adenosine deaminase or kinase [89, 90] or preventing its
transport [91, 92], offer protection against ischemic neuronal
damage in different in vivo ischemia models. Moreover,
adenosine infusion into the ischemic striatum during tran-
sient focal ischemia proves to significantly ameliorate the
neurological outcome and reduce infarct volume [93].
A temporal correlation exists between adenosine outflow
and synaptic potential inhibition in rat hippocampal slices
during ischemia-like conditions [84, 88]. Synaptic inhibition
during ischemia is greatly dependent on adenosine, which,
by stimulating A1 receptors, exerts a protective role by
reducing the Ca
2+ influx, thus counteracting the presynaptic
release of excitatory neurotransmitters [55, 94]a n d ,i n
particular, glutamate, which exerts an excitotoxic role during
ischemia mainly by overstimulation of NMDA receptors
[95]. By directly increasing the K
+ and Cl
− ion conductan-
Fig. 5 Schematic drawing of
intracellular and extracellular
adenosine formation. In the
extracellular space, adenosine
and ATP act on own purinergic
receptor subtypes: P1 and P2
receptors, respectively. ADP
adenosine diphosphate, AMP
adenosine monophosphate, ATP
adenosine triphosphate, e5′-NT
ecto-5′-nucleotidase,
5′-NT 5′-nucleotidase, NTDPase
ecto-nucleoside triphosphate
diphosphohydrolases, P1
adenosine receptor, P2 ATP
receptor, SAH S-adenosylhomo-
cysteine, T bidirectional
nucleoside transporter.
(Modified from [142])
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thus reducing neuronal excitability [96]. Consequent reduc-
tions in cellular metabolism and energy consumption [97]
and moderate lowering of the body/brain temperature [98]
are protective in ischemia.
A1 receptor agonists are shown to attenuate ischemic or
excitotoxic neuronal damage in both in vitro and in vivo
models of cerebral ischemia (for review, see [99, 100]). In
accordance, adenosine A1 antagonists given acutely exac-
erbate the damage induced by ischemia in different animal
models of ischemia. An unselective A1 receptor antagonist,
theophylline, increased mortality [101, 102]. Unlike acute
treatment, chronic administration of A1 agonists worsened
survival and increased neuronal loss [103], a phenomenon
thought to depend on A1 receptor desensitization.
Although data converge in demonstrating a neuroprotec-
tiveeffectofadenosinethroughA1 receptors during ischemia,
the use of selective A1 agonists is hampered by unwanted
peripheral effects, e.g. sedation, bradycardia, hypotension
[104]. Von Lubitz and co-workers [105]h a v er e p o r t e dt h a t
post-ischemic administration of the A1 receptor agonist
adenosine amine congener (ADAC), which induces fewer
undesirable effects, increases survival in gerbils. Moreover,
we may consider that administration of agents that elevate
the local concentration of adenosine at the injury site, by
inhibiting its metabolism to inosine or rephosphorylation to
AMP or reuptake, may have the advantage of restricting the
effect of such inhibitors to areas of injury-induced adenosine
release [106].
More recently, the role of A2A receptors in ischemic
neuroprotection has been studied. Gao and Phillis [107]
demonstrated for the first time that the non-selective A2A
receptor antagonist CGS 15943 reduces cerebral ischemic
injury in the gerbil following global forebrain ischemia.
Subsequently, many reports have confirmed the neuropro-
tective role of A2A receptor antagonists in different models of
ischemia. The selective A2A receptor antagonist SCH 58261
reduced ischemic brain damage in neonatal [108] and adult
[83, 109] rat models of focal cerebral ischaemia. The same
antagonist, subchronically administered, was protective
against both brain damage and neurological deficit in the
adult rat model of focal cerebral ischemia [110, 111]. Studies
in A2A receptor knockout mice supported the neuroprotective
role of A2A receptor antagonists on ischemic brain damage
[112]. The beneficial effects of A2A antagonists in stroke
were mainly attributed to reduced glutamate outflow [83,
110, 113]. Prolonged application of the A2A selective agonist
CGS 21680 significantly reduced synaptic depression
brought about by OGD in the hippocampus [59] and the
same agonist promotes glutamate release under normoxic
and ischemic conditions [70, 71, 114, 115]. In addition to
neurones, adenosine A2A receptors are located on microglia
[116, 117] and astrocytes [118]. On glial cells, A2A receptors
mediate inhibition of the glutamate uptake transporter, GLT-
1, and stimulate glutamate outflow [119]. A2A antagonists
prevent the increase in glutamate levels induced by glutamate
uptake inhibitors [120]. Therefore, the protective effects of
A2A antagonists in brain ischemia may be largely due to
reduced glutamate outflow from neurones and glial cells.
Further support of a major role for glia in the neuro-
protective effect of A2A antagonism in ischemia comes from
the observation that subchronic administration of the A2A
receptor antagonist SCH 58261 reduces p38 mitogen-
activated protein kinase (MAPK) activation in striatal and
cortical microglia 24 h after permanent focal ischemia [111].
Evidence indicates that p38 MAPK is activated in glia up to
24 h after ischemia [121, 122] and is involved, through
transcriptional mechanisms, in neuronal death [123, 124].
Since SCH 58261 reduces glutamate outflow in the first
hours after ischemia [83], reduced p38 MAPK activation
may be due to a direct effect on glial A2A receptors or may
be secondary to a reduction in the excitotoxic cascade that
primes p38 activation [125] .T h ei m p o r t a n c eo fA 2A
receptors under ischemia is highlighted by the observation
that A2A receptor expression increases on neurones and
microglia after ischemia [126]. Selective inactivation of A2A
receptors on bone-marrow-derived cells (wild-type mice
transplanted with A2A receptor knockout bone marrow cells)
attenuates infarct volumes and ischemia-induced expression
of several proinflammatory cytokines in the brain [127].
Therefore, protective effects of A2A antagonists may be
attributed to inhibition of inflammation product production.
In several studies, A2A receptor agonists have been found
to be protective in the global ischemia model in the gerbil
[128, 129]. Jones and co-workers [130]s h o wt h a tp e r i p h e r a l
administration of the A2A receptor agonist CGS 21680
protects the hippocampus against kainate-induced excitotox-
icity. However, the direct injection of CGS 21680 into the
hippocampus failed to afford protection, while the A2A anta-
gonist ZM 241385, when injected directly into the hippo-
campus, reduced kainate-induced neuronal damage [131].
These data suggest that the neuroprotective properties of A2A
agonists are mainly due to peripherally mediated effects.
Major mechanisms that may account for A2A-mediated
protection include inhibition of platelet aggregation and
vasodilation [89] and anti-inflammatory actions. A2A recep-
tors on neutrophils may account for inhibition of adhesion to
endothelial cells and ensuing production of free radicals
[132, 133].
On this basis, adenosine and its receptors are considered
targets for therapeutic implementation in the treatment of
stroke. At the moment, a possible adenosynergic therapeutic
strategy after ischaemia that is worth consideration is that of
increasing adenosine concentrations at the ischemic sites by
inhibitors of adenosine metabolism or reuptake in association
with adenosine A2A antagonists. When considering the
Purinergic Signalling (2007) 3:299–310 305possible use of adenosine kinase inhibitors, it should be
taken into account that adenosine represents only a small
percentage of nucleotide content [134], therefore inhibition
of its rephosphorylation to ATP by adenosine kinase
inhibitors does not weigh upon the ATP content.
The few studies present inthe literatureconcerningthe role
of A3 receptors in the pathophysiology of cerebral ischemia
are rather contradictory. We have demonstrated that selective
antagonism of A3 receptors facilitates the recovery of
synaptic activity induced by ischemic preconditioning in rat
hippocampal slices [81]. A harmful role of A3 receptors
during in vitro OGD was confirmed by our observation that
blocking the A3 adenosine receptor consistently abolishes or
delays the occurrence of anoxic depolarization (AD) and sig-
nificantly protects from the irreversible disruption of excit-
atory neurotransmission caused by a severe ischemic episode
[135]. These results are in agreement with the observation
that acute administration of a selective adenosine A3 agonist
exacerbates the damage elicited by global ischemia in the
gerbil [136]. On the contrary, it was demonstrated that
chronic pre-ischemic administration of an A3 agonist protects
against ischemic neuronal damage [136]. This effect may be
attributed to desensitisation of A3 receptors. In fact, both
human and rat A3 receptors are desensitised within a few
minutes after agonist exposure [137, 138].
Contrary to the above information, Hentschel and col-
leagues [139] demonstrated that under hypoxic conditions,
selective activation of A3 adenosine receptors brings about an
inhibition of excitatory neurotransmission on cortical neuro-
nes, indicating that A3 receptors may sustain the neuro-
protective action of adenosine induced by A1 receptors.
Consistent with these reports, mice lacking A3 adenosine
receptors show increased neurodegeneration in response to
repeated episodes of moderate hypoxia [140]o ra ni n c r e a s e
in cerebral infarction after transient ligation of the middle
cerebral artery [141]. These opposite results regarding an
excitatory or inhibitory role of A3 receptors on synaptic
activity under hypoxia/ischemia may be reconciled by our
recent data [135], suggesting that in a first phase of ischemia,
A3 receptors play a protective synergistic role with A1
receptors. Severe ischemia would transform the A3 receptor-
mediated effects from protective to injurious.
Taken together, these data suggest that the outcome of
A3 receptor stimulation on synaptic transmission during
hypoxic/ischemic phenomena depends on the intensity and
duration of stimulation.
Concluding remarks
Purinergic signalling, e.g. adenosine and ATP, by activating
specific membrane receptors (P1 and P2 respectively), is
strictly correlated in orchestrating brain cell functions either
under physiological normoxic or ischemic circumstances.
However, the respectivecontributionofeachsingleelement is
hard to discern from the total outcome, due to the rapid and
ubiquitous enzymatic interconversion of these molecules.
In the brain, both compounds are likely to play a role in
neuronal activity, and the inhibitory action of endogenous
adenosine in excitatory neurotransmission (mainly due to A1
receptor activation) is well documented. Conversely our
data, in line with previous observations in the literature,
suggest that tonic activation of P2 receptors contributes to
excitatory transmission in the hippocampus. Such an effect is
modest, but it is unmasked by the application of P2 pu-
rinergic antagonists that reduce evoked synaptic responses.
An inhibitory effect elicited by exogenous ATP applica-
tion has been frequently described and is mostly due to
enzymatic degradation to adenosine and the subsequent
activation of A1 receptors. However, our evidence demon-
strates that ATP itself may inhibit hippocampal synaptic
transmission since an even more pronounced effect is
observed when enzymatic ATP degradation is blocked.
Moreover, in our studies in the hippocampus, a potentiation
of neurotransmission by the ATP analogue, ATPγS,
develops a few minutes after the inhibitory effect has been
washed out, and it persists for 45 min to 1 h. Within the
brain, ATP is involved in the synaptic plasticity phenom-
enon and may be an important mediator of long-lasting ef-
fects in synaptic plasticity.
Either adenosine or ATP seems to become a particularly
important signalling molecule under pathological conditions,
such as ischemia, when the extracellular concentration of
either compound drastically rises. It is well known that
adenosine exerts important neuroprotective effects during
brain ischemic insults by activating adenosine A1 receptors,
which profoundly inhibit synaptic transmission and in
particular the release of glutamate, known to contribute to
ischemic damage. Under severe ischemia, a prolonged stim-
ulation of both A2A and A3 receptors may be deleterious.
The role of endogenously released ATP during cerebral
ischemia is mainly deleterious, as found in our work and in
the literature, since the application of P2 antagonists always
results in a reduction in ischemic damage. The mechanisms
underlying these effects are still unknown, but they can be
correlated to the tonic excitatory action of endogenous ATP
found in many brain regions (for example in the hippo-
campus and prefrontal cortex).
Purinergic signalling has an ancient phylogenetic origin.
ExpressionofP2receptorsoncellmembraneandresponsesto
extracellular ATP are found in primitive prokaryotic species
uptoevolvedanimalsandplants,suggestinganimportantand
highly conserved role of extracellular purine nucleotides
during evolution. Similarly, ontogenetic development in
several species seems to involve purinergic signalling,
especially during its first stages. Our observation that hMSCs,
306 Purinergic Signalling (2007) 3:299–310an undifferentiated line of cells able to originate a number of
different cell lineages (adipocytes, chondrocytes, osteoblasts,
neurones), spontaneously release ATP into the extracellular
space and express functional purinergic P2 receptors, which
modulate different kinds of membrane currents, and that ATP,
during the early stages of culture, inhibits proliferation
indicates an autocrine/paracrine mechanism of action for
extracellular ATP in modulating cell functions of undifferen-
tiated stem cells at early developmental stages. Such effects
may be important in brain neurogenesis during development
and in responses to neurodegenerative stimuli.
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